Clinical Trial Update: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD [Phase 3]

View source ↗

Summary

Phase 3 study of PBF-1681 (ferric citrate) for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• PBF-1681 (Ferric Citrate) (ferric citrate)

Snippet

Sponsor: Panion & BF Biotech Inc. | Conditions: Anemia of Chronic Kidney Disease | Phase 3 | Status: COMPLETED